Prescriber's Corner

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer

Patrick J. Fleming Jr., PharmD, BCOP, Sylvia Karpio, PharmD candidate, and Nicholas Lombardo, PharmD candidate

From University of Illinois at Chicago, Chicago, Illinois

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Patrick J. Fleming Jr., PharmD, BCOP, University of Illinois at Chicago, 840 S Wood St., Chicago, IL 60607. E-mail: pflemi2@uic.edu


J Adv Pract Oncol 2021;12(7):747–752 | https://doi.org/10.6004/jadpro.2021.12.7.8 | © 2021 Harborside™


  

ABSTRACT

Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. A confirmatory phase III trial evaluating sacituzumab govitecan vs. chemotherapy of the provider’s choice was published in April 2021. Based on this trial, the FDA granted sacituzumab govitecan full regulatory approval. This antibody-drug conjugate is composed of a monoclonal antibody targeted at Trop-2 and contains the active metabolite of irinotecan, SN-38, as a cytotoxic side moiety. In a phase III clinical trial, sacituzumab govitecan demonstrated a median progression-free survival of 5.7 months vs. 1.7 months with chemotherapy. It is now an additional option for patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.